SG11201608608PA - Rapid relief of motor fluctuations in parkinson's disease - Google Patents

Rapid relief of motor fluctuations in parkinson's disease

Info

Publication number
SG11201608608PA
SG11201608608PA SG11201608608PA SG11201608608PA SG11201608608PA SG 11201608608P A SG11201608608P A SG 11201608608PA SG 11201608608P A SG11201608608P A SG 11201608608PA SG 11201608608P A SG11201608608P A SG 11201608608PA SG 11201608608P A SG11201608608P A SG 11201608608PA
Authority
SG
Singapore
Prior art keywords
parkinson
disease
rapid relief
motor fluctuations
fluctuations
Prior art date
Application number
SG11201608608PA
Other languages
English (en)
Inventor
Richard P Batycky
Martin Freed
Michael M Lipp
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of SG11201608608PA publication Critical patent/SG11201608608PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG11201608608PA 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease SG11201608608PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/034778 WO2015163840A1 (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease

Publications (1)

Publication Number Publication Date
SG11201608608PA true SG11201608608PA (en) 2016-11-29

Family

ID=54332876

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608608PA SG11201608608PA (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease

Country Status (14)

Country Link
US (2) US20170296498A1 (enExample)
EP (2) EP3134077A4 (enExample)
JP (1) JP2017513866A (enExample)
KR (2) KR20210144946A (enExample)
CN (2) CN106659685B (enExample)
AU (2) AU2014391721B2 (enExample)
BR (1) BR112016024502A8 (enExample)
CA (1) CA2946165C (enExample)
IL (2) IL309959A (enExample)
MX (1) MX2016013741A (enExample)
RU (1) RU2698330C2 (enExample)
SG (1) SG11201608608PA (enExample)
WO (1) WO2015163840A1 (enExample)
ZA (1) ZA201607833B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
EP3735298A4 (en) * 2018-01-05 2021-10-06 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF LEVODOPA POWDER BY N BY AN OLFACTORIC PRECISION DEVICE
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
PT1531798E (pt) 2002-03-20 2012-09-10 Civitas Therapeutics Inc Administração pulmonar de levodopa
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2008156586A2 (en) 2007-06-12 2008-12-24 Alkermes, Inc. Inhalation device for powdered substances
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
US8703809B2 (en) * 2008-06-30 2014-04-22 Novartis Ag Combination products
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
CN104884046A (zh) * 2012-10-22 2015-09-02 丝维塔斯治疗公司 用于快速缓解帕金森病的左旋多巴制剂
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use

Also Published As

Publication number Publication date
CN106659685B (zh) 2021-02-05
BR112016024502A8 (pt) 2021-06-29
CA2946165A1 (en) 2015-10-29
AU2014391721A1 (en) 2016-11-03
IL248445A0 (en) 2016-12-29
AU2014391721B2 (en) 2020-07-16
AU2020239754A1 (en) 2021-01-14
KR20170008754A (ko) 2017-01-24
RU2016144340A (ru) 2018-05-22
EP3831375A1 (en) 2021-06-09
US20230053976A1 (en) 2023-02-23
US20170296498A1 (en) 2017-10-19
KR20210144946A (ko) 2021-11-30
IL309959A (en) 2024-03-01
CA2946165C (en) 2022-10-18
AU2020239754B2 (en) 2022-06-23
BR112016024502A2 (pt) 2017-08-15
JP2017513866A (ja) 2017-06-01
RU2698330C2 (ru) 2019-08-26
MX2016013741A (es) 2017-04-06
EP3134077A1 (en) 2017-03-01
ZA201607833B (en) 2018-08-29
CN113209055A (zh) 2021-08-06
CN106659685A (zh) 2017-05-10
EP3134077A4 (en) 2017-12-20
RU2016144340A3 (enExample) 2018-05-22
WO2015163840A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
IL280530A (en) Decarboxylase aromatic amino acid-encoding phylonucleotides for the treatment of Parkinson's disease
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
GB201418171D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418170D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418166D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418169D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
IL247085A0 (en) Methods for treating Alzheimer's disease
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
GB201418172D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
SG11201702819YA (en) Skin cosmetic
ZA201605341B (en) Methods of treating alzheimer's disease
IL263188B (en) Treatment for Parkinson's disease
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
HUE044153T2 (hu) Apilimod melanóma kezelésében történõ alkalmazásra
EP3105687A4 (en) Biomedical research database development and uses
GB201417163D0 (en) Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
EP3177304A4 (en) Therapeutic nanoparticles for accumulation in the brain
EP3217973A4 (en) Melatonin in autoimmune disease
EP3109636A4 (en) Biomarker for parkinson's disease and use therefor
GB2553527B (en) Headgear suitable for use in hydrotherapy
ZA201607833B (en) Rapid relief of motor fluctuations in parkinson's disease
GB2527909B (en) Improvements in and relating to imaging of the eye
HK1228769A1 (en) Rapid relief of motor fluctuations in parkinson's disease
ZA201807944B (en) Treatment for parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment